Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Mol Sci ; 19(9)2018 Sep 04.
Article in English | MEDLINE | ID: mdl-30181440

ABSTRACT

Molecular factors involved in neuroprotection are key in the design of novel multitarget drugs in aging and neurodegeneration. AVCRI104P3 is a huprine derivative that exhibits potent inhibitory effects on human AChE, BuChE, and BACE-1 activities, as well as on AChE-induced and self-induced Aß aggregation. More recently, cognitive protection and anxiolytic-like effects have also been reported in mice treated with this compound. Now, we have assessed the ability of AVCRI104P3 (0.43 mg/kg, 21 days) to modulate the levels of some proteins involved in the anti-apoptotic/apoptotic processes (pAkt1, Bcl2, pGSK3ß, p25/p35), inflammation (GFAP and Iba1) and neurogenesis in C57BL/6 mice. The effects of AVCRI104P3 on AChE-R/AChE-S isoforms have been also determined. We have observed that chronic treatment of C57BL/6 male mice with AVCRI104P3 results in neuroprotective effects, increasing significantly the levels of pAkt1 and pGSK3ß in the hippocampus and Bcl2 in both hippocampus and cortex, but slightly decreasing synaptophysin levels. Astrogliosis and neurogenic markers GFAP and DCX remained unchanged after AVCRI104P3 treatment, whereas microgliosis was found to be significantly decreased pointing out the involvement of this compound in inflammatory processes. These results suggest that the neuroprotective mechanisms that are behind the cognitive and anxiolytic effects of AVCRI104P3 could be partly related to the potentiation of some anti-apoptotic and anti-inflammatory proteins and support the potential of AVCRI104P3 for the treatment of brain dysfunction associated with aging and/or dementia.


Subject(s)
Aging/genetics , Aminoquinolines/administration & dosage , Brain/metabolism , Gene Regulatory Networks/drug effects , Neuroprotective Agents/administration & dosage , Acetylcholinesterase/genetics , Acetylcholinesterase/metabolism , Aging/drug effects , Aging/metabolism , Aminoquinolines/pharmacology , Animals , Brain/drug effects , Doublecortin Protein , GPI-Linked Proteins/genetics , GPI-Linked Proteins/metabolism , Gene Expression Regulation/drug effects , Glycogen Synthase Kinase 3 beta/metabolism , Male , Mice , Mice, Inbred C57BL , Neuroprotective Agents/pharmacology , Phosphorylation/drug effects , Proto-Oncogene Proteins c-akt/metabolism , Proto-Oncogene Proteins c-bcl-2/metabolism , Synaptophysin/metabolism
2.
Basic Clin Pharmacol Toxicol ; 122(1): 94-103, 2018 Jan.
Article in English | MEDLINE | ID: mdl-28724203

ABSTRACT

Huprine X (HX) is a synthetic anticholinesterasic compound that exerts a potent inhibitory action on acetylcholinesterase (AChE) activity, an agonist effect on cholinergic receptors, neuroprotective activity in different neurotoxicity models in vivo and in vitro and cognition enhancing effects in non-transgenic (C57BL/6) and transgenic (3xTg-AD, APPswe) mice. In this study, we assessed the ability of HX (0.8 mg/kg, 21 days) to prevent the damage induced by kainic acid (KA; 28 mg/kg) regarding apoptosis, glia reactivity and neurogenesis in mouse brain. KA administration significantly modified the levels of pAkt1, Bcl2, pGSK3ß, p25/p35, increased the glial cell markers and reduced the neurogenesis process. We also observed that pre-treatment with HX significantly reduced the p25/p35 ratio and increased synaptophysin levels, which suggests a protective effect against apoptosis and an improvement of neuroplasticity. The increase in GFAP (88%) and Iba-1 (72%) induced by KA was totally prevented by HX pre-treatment, underlying a relevant anti-inflammatory action of the anticholinesterasic drug. Our findings highlight the potential of HX, in particular, and of AChEIs, in general, to treat a number of diseases that course with both cognitive deficits and chronic inflammatory processes.


Subject(s)
Aminoquinolines/pharmacology , Brain/drug effects , Encephalitis/prevention & control , Heterocyclic Compounds, 4 or More Rings/pharmacology , Neuroprotective Agents/pharmacology , Neurotoxicity Syndromes/prevention & control , Aminoquinolines/therapeutic use , Animals , Apoptosis/drug effects , Biomarkers/metabolism , Brain/cytology , Brain/pathology , Cholinesterase Inhibitors/pharmacology , Cholinesterase Inhibitors/therapeutic use , Disease Models, Animal , Encephalitis/chemically induced , Encephalitis/pathology , Heterocyclic Compounds, 4 or More Rings/therapeutic use , Humans , Kainic Acid/toxicity , Male , Mice , Mice, Inbred C57BL , Neuroglia/drug effects , Neuroglia/metabolism , Neuronal Plasticity/drug effects , Neuroprotective Agents/therapeutic use , Neurotoxicity Syndromes/etiology , Neurotoxicity Syndromes/pathology
3.
Neurodegener Dis ; 10(1-4): 96-9, 2012.
Article in English | MEDLINE | ID: mdl-22236498

ABSTRACT

BACKGROUND: Multifactorial diseases such as Alzheimer's disease (AD) should be more efficiently tackled by drugs which hit multiple biological targets involved in their pathogenesis. We have recently developed a new family of huprine-tacrine heterodimers, rationally designed to hit multiple targets involved upstream and downstream in the neurotoxic cascade of AD, namely ß-amyloid aggregation and formation as well as acetylcholinesterase catalytic activity. OBJECTIVE: In this study, the aim was to expand the pharmacological profiling of huprine-tacrine heterodimers investigating their effect on muscarinic M(1) receptors as well as their neuroprotective effects against an oxidative insult. METHODS: Sprague-Dawley rat hippocampus homogenates were used to assess the specific binding of two selected compounds in competition with 1 nM [(3)H]pirenzepine (for M(1) receptors) or 0.8 nM [(3)H]quinuclidinyl benzilate (for M(2) receptors). For neuroprotection studies, SHSY5Y cell cultures were subjected to 250 µM hydrogen peroxide insult with or without preincubation with some huprine-tacrine heterodimers. RESULTS: A low nanomolar affinity and M(1)/M(2) selectivity has been found for the selected compounds. Huprine-tacrine heterodimers are not neurotoxic to SHSY5Y cells at a range of concentrations from 1 to 0.001 µM, and some of them can protect cells from the oxidative damage produced by hydrogen peroxide at concentrations as low as 0.001 µM. CONCLUSION: Even though it remains to be determined if these compounds act as agonists at M(1) receptors, as it is the case of the parent huprine Y, their low nanomolar M(1) affinity and neuroprotective effects expand their multitarget profile and increase their interest as disease-modifying anti-Alzheimer agents.


Subject(s)
Aminoquinolines/metabolism , Heterocyclic Compounds, 4 or More Rings/metabolism , Protein Multimerization/physiology , Tacrine/metabolism , Analysis of Variance , Animals , Cell Line, Tumor , Cell Survival/drug effects , Dose-Response Relationship, Drug , Hippocampus/drug effects , Hippocampus/metabolism , Humans , Hydrogen Peroxide/pharmacology , Muscarinic Antagonists/pharmacokinetics , Neuroblastoma/pathology , Oxidative Stress/drug effects , Oxidative Stress/physiology , Pirenzepine/pharmacokinetics , Protein Binding/drug effects , Protein Multimerization/drug effects , Quinuclidinyl Benzilate/pharmacokinetics , Rats , Rats, Sprague-Dawley , Structure-Activity Relationship , Tritium/metabolism
4.
J Med Chem ; 55(2): 661-9, 2012 Jan 26.
Article in English | MEDLINE | ID: mdl-22185619

ABSTRACT

A family of huprine-tacrine heterodimers has been developed to simultaneously block the active and peripheral sites of acetylcholinesterase (AChE). Their dual site binding for AChE, supported by kinetic and molecular modeling studies, results in a highly potent inhibition of the catalytic activity of human AChE and, more importantly, in the in vitro neutralization of the pathological chaperoning effect of AChE toward the aggregation of both the ß-amyloid peptide (Aß) and a prion peptide with a key role in the aggregation of the prion protein. Huprine-tacrine heterodimers take on added value in that they display a potent in vitro inhibitory activity toward human butyrylcholinesterase, self-induced Aß aggregation, and ß-secretase. Finally, they are able to cross the blood-brain barrier, as predicted in an artificial membrane model assay and demonstrated in ex vivo experiments with OF1 mice, reaching their multiple biological targets in the central nervous system. Overall, these compounds are promising lead compounds for the treatment of Alzheimer's and prion diseases.


Subject(s)
Alzheimer Disease/drug therapy , Aminoquinolines/chemical synthesis , Amyloid beta-Peptides/antagonists & inhibitors , Cholinesterase Inhibitors/chemical synthesis , Heterocyclic Compounds, 4 or More Rings/chemical synthesis , Prion Diseases/drug therapy , Prions/antagonists & inhibitors , Tacrine/analogs & derivatives , Tacrine/chemical synthesis , Acetylcholinesterase/chemistry , Acetylcholinesterase/metabolism , Aminoquinolines/pharmacokinetics , Aminoquinolines/pharmacology , Amyloid beta-Peptides/chemistry , Animals , Brain/metabolism , Butyrylcholinesterase/chemistry , Cholinesterase Inhibitors/pharmacokinetics , Cholinesterase Inhibitors/pharmacology , Heterocyclic Compounds, 4 or More Rings/pharmacokinetics , Heterocyclic Compounds, 4 or More Rings/pharmacology , Humans , Membranes, Artificial , Mice , Models, Molecular , Peptide Fragments/antagonists & inhibitors , Peptide Fragments/chemistry , Permeability , Prions/chemistry , Recombinant Proteins/chemistry , Stereoisomerism , Structure-Activity Relationship , Tacrine/pharmacokinetics , Tacrine/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...